Clinical trialNCT01494506CompletedPhase 3Interventional

Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer

SponsorMerrimack PharmaceuticalsEnrollment417Metastatic Pancreatic Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The study is an open label, randomized phase 3 study of MM-398 with or without 5-Fluorouracil (5-FU) and Leucovorin (also known as folinic acid), versus 5-FU and leucovorin in metastatic pancreatic cancer patients who have progressed on prior gemcitabine based therapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Eliel Bayever, MD
Merrimack Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

79 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Facility name not stated
Buenos Aires, Argentina
Facility name not stated
Rosario, Argentina
Facility name not stated
Santa Fe, Argentina

Australia

Facility name not stated
Westmead, New South Wales, Australia
Facility name not stated
Kurralta Park, South Australia, Australia
Facility name not stated
Boxhill, Victoria, Australia
Facility name not stated
Heidelberg, Victoria, Australia
Facility name not stated
Melbourne, Victoria, Australia
Facility name not stated
Nedlands, Western Australia, Australia

Brazil

Facility name not stated
Belo Horizonte, Brazil
Facility name not stated
Ijuí, Brazil
Facility name not stated
Passo Fundo, Brazil
Facility name not stated
Porto Alegre, Brazil
Facility name not stated
São Paulo, Brazil

Canada

Facility name not stated
Montreal, Quebec, Canada

Czechia

Facility name not stated
Hořovice, Czechia
Facility name not stated
Olomouc, Czechia
Facility name not stated
Prague, Czechia
Facility name not stated
Příbram, Czechia

France

Facility name not stated
Bordeaux, France
Facility name not stated
Lille, France
Facility name not stated
Marseille, France

Germany

Facility name not stated
Berlin, Germany
Facility name not stated
Jens, Germany
Facility name not stated
Munich, Germany
Facility name not stated
Ulm, Germany

Hungary

Facility name not stated
Budapest, Hungary
Facility name not stated
Pécs, Hungary
Facility name not stated
Szeged, Hungary
Facility name not stated
Szolnok, Hungary
Facility name not stated
Szombathely, Hungary

Italy

Facility name not stated
Castellana Grotte, Italy
Facility name not stated
Genova, Italy
Facility name not stated
Legnano, Italy
Facility name not stated
Naples, Italy
Facility name not stated
Roma, Italy

South Africa

Facility name not stated
Port Elizabeth, South Africa
Facility name not stated
Pretoria, South Africa
Facility name not stated
Western Cape, South Africa

South Korea

Facility name not stated
Hwasun-gun, South Korea

39 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Fluorouracil →Leucovorin →MM-398

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Nov 2011
Primary completion: 28 Feb 2014
Completion: 31 Oct 2015
Last update posted: 17 Jun 2016
Registered enrollment: 417
Registry id: NCT01494506

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.